5/28/2013

The FDA has granted priority review status to Celgene International's supplemental new drug application for Abraxane, or paclitaxel. The application seeks to extend the use of Abraxane, in combination with gemcitabine, as a front-line treatment for advanced pancreatic cancer.

Related Summaries